Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
NEW YORK, NY, January 2, 2008 — Pfizer announced on December 31 that it has completed the cash tender offer for the outstanding shares of common stock of Coley Pharmaceutical Group, Inc., a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases. Covington & Burling LLP advised Pfizer in the $164 million transaction. Pfizer, the world’s largest research-based biomedical and pharmaceutical company, discovers and develops innovative medicines to treat and to help prevent disease for both people and animals. Coley is a pioneer in a new class of drug candidates called TLR Therapeutics, which work by stimulating or blocking important immune system receptors, called Toll-like receptors (TLRs), which, in turn, direct the immune system to fight disease. Coley has discovered proprietary clinical stage drug candidates targeting TLRs 7, 8 and 9. The Covington corporate team included partners Scott Smith and Peter Schwartz, and associates Peter Bogdanow, Michelle Garcia* and Meenakshi Roy*. All are resident in the firm’s New York office. Also involved in the deal were Washington-based Lee Tiedrich and Kathleen Gallagher-Duff (IP), Kendra Roberson and Mike Francese (benefits), Scott Cunningham (regulatory), and Corinne Goldstein (environmental), and San Francisco-based Jim Snipes and Chelsea Tanaka-Delgado (licensing; collaboration agreement).
*Not yet admitted to practice.